Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STI-5656 (Abivertinib) in Hospitalized COVID-19
NCT04528667Phase 2Completed
- Sponsor
- Sorrento Therapeutics
- Start
- Jan 2021
- Primary completion
- Aug 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of abivertinib in coronavirus disease 2019 (COVID-19), sponsored by Sorrento Therapeutics. Started Jan 2021; status: completed.
02
Drugs
abivertinib
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04528667.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04528667.